TY - JOUR
T1 - Serial immune evaluation of cyclosporine- and placebo-treated multiple sclerosis patients
AU - Kerman, Ronald H.
AU - Wolinsky, Jerry S.
AU - Nath, Avindra
AU - Simon Sears, E.
N1 - Funding Information:
Supported in part by funds provided from The Sandoz Pharmaceutical Corporation and The National Multiple Sclerosis Society. The authors acknowledge the expert assistance of Ms. Catherine Weisbrodt, R.N. in this study.
PY - 1988/7
Y1 - 1988/7
N2 - During an ongoing clinical trial of cyclosporine (CsA) immunosuppression therapy for chronic progressive multiple sclerosis (MS), a comparison was made of the immune responses of 18 CsA- and 18 placebo (P)-treated MS patients. Patients randomized to receive either CsA or P had identical entry immune profiles. However, these MS patients displayed significantly increased T-helper: T-suppressor (TH : TS) ratios (P < 0.01), percentage (%) active-T (P < 0.01), % Ia+-T (P < 0.05) and % Ta1+-T (P < 0.01) cell phenotypes when compared to age-matched normal controls. Further, the MS-P-treated patients displayed significant increases (all P < 0.01) in % pan-T, % helper-T, % active-T and % Ta1+-T cell phenotypes as well as panel mixed lymphocyte culture (panel MLC) functional responsiveness from entry to cumulative 12-month study data. In contrast, the MS-CsA-treated patients only displayed an increased % pan-T cell phenotype. The cumulative 12-month follow-up data showed that the MS-P-treated patients displayed significantly higher immune parameters than the MS-CsA-treated patients for % pan-T (P < 0.05), % helper-T (P < 0.01), TH : TS ratio (P < 0.05), % active-T (P < 0.01), % Ta1+-T cells (P < 0.01) and panel MLC stimulation index (P < 0.01). Thus, MS-CsA-treated patients did not display the progressive immune activation seen on serial evaluation during the follow-up time period that characterized the placebo-treated MS group.
AB - During an ongoing clinical trial of cyclosporine (CsA) immunosuppression therapy for chronic progressive multiple sclerosis (MS), a comparison was made of the immune responses of 18 CsA- and 18 placebo (P)-treated MS patients. Patients randomized to receive either CsA or P had identical entry immune profiles. However, these MS patients displayed significantly increased T-helper: T-suppressor (TH : TS) ratios (P < 0.01), percentage (%) active-T (P < 0.01), % Ia+-T (P < 0.05) and % Ta1+-T (P < 0.01) cell phenotypes when compared to age-matched normal controls. Further, the MS-P-treated patients displayed significant increases (all P < 0.01) in % pan-T, % helper-T, % active-T and % Ta1+-T cell phenotypes as well as panel mixed lymphocyte culture (panel MLC) functional responsiveness from entry to cumulative 12-month study data. In contrast, the MS-CsA-treated patients only displayed an increased % pan-T cell phenotype. The cumulative 12-month follow-up data showed that the MS-P-treated patients displayed significantly higher immune parameters than the MS-CsA-treated patients for % pan-T (P < 0.05), % helper-T (P < 0.01), TH : TS ratio (P < 0.05), % active-T (P < 0.01), % Ta1+-T cells (P < 0.01) and panel MLC stimulation index (P < 0.01). Thus, MS-CsA-treated patients did not display the progressive immune activation seen on serial evaluation during the follow-up time period that characterized the placebo-treated MS group.
KW - Immune evaluation
KW - Multiple sclerosis
KW - serial
UR - http://www.scopus.com/inward/record.url?scp=0023934069&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023934069&partnerID=8YFLogxK
U2 - 10.1016/0165-5728(88)90053-7
DO - 10.1016/0165-5728(88)90053-7
M3 - Article
C2 - 2968363
AN - SCOPUS:0023934069
VL - 18
SP - 325
EP - 331
JO - Advances in Neuroimmunology
JF - Advances in Neuroimmunology
SN - 0165-5728
IS - 4
ER -